Emavusertib

Phase 2Biologic

NNational Cancer Institute (NCI)

Emavusertib is one of 78 biologic programs targeting Metastatic Urothelial Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Urothelial CarcinomaRecruiting

Chronic Lymphocytic LeukemiaRecruiting

Central Nervous System LymphomaRecruiting

Metastatic Urothelial CarcinomaPhase 1

Recruiting

Chronic Lymphocytic LeukemiaPhase 2

Recruiting

Central Nervous System LymphomaPhase 2

Recruiting

Competition

Competitive Landscape

94 competitors in Chronic Lymphocytic Leukemia

#DrugCompanyPhaseTrials

Gazyva

Roche

Phase 3

59 2

Fludara

Sanofi

Phase 3

38 3

Venclexta

AbbVie

Phase 3

51 4

Calquence

AstraZeneca

Phase 3

27 5

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

40 6

Brukinsa

BBeOne Medicines

Phase 3

17 7

Keytruda

Merck & Co.

Phase 3

2 8

Adcetris

Pfizer

Phase 3

1 9

Beqalzi

BBeOne Medicines

Phase 3

8 10

Campath

GGenzyme, a Sanofi Company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Central Nervous System Lymphoma

NCT03328078

Phase 1Recruiting

Metastatic Colorectal Adenocarcinoma

NCT06696768

Q2 2027

Phase 1Recruiting

Metastatic Urothelial Carcinoma

NCT06439836

Q4 2027

Phase 2Recruiting

Chronic Lymphocytic Leukemia

NCT07271667

Phase 2Not yet recruiting

Myelodysplastic Syndrome

NCT07463820

Q2 2029

Phase 2Recruiting

Acute Myeloid Leukemia

NCT05564390

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome2 trials

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Suspended·CCuris, Inc.·Phase 1/2·NCT04278768·366 enrolled

A Phase II Study of Combination Therapy With Luspatercept in Lower Risk Myelodysplasia: A Tier 1 MyeloMATCH Substudy

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07463820·270 enrolled

Chronic Lymphocytic Leukemia1 trial

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Recruiting·CCuris, Inc.·Phase 2·NCT07271667·108 enrolled

Biliary Tract Cancer1 trial

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Not yet recruiting·WWashington University School of Medicine·Phase 1·NCT07107750·48 enrolled

Central Nervous System Lymphoma1 trial

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Recruiting·CCuris, Inc.·Phase 1/2·NCT03328078·152 enrolled

Acute Myeloid Leukemia1 trial

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05564390·2,000 enrolled

3 more indications

Metastatic Pancreatic Ductal Adenocarcinoma1 trial

A Phase I Clinical Trial of CA-4948 in Combination With Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma

Suspended·NNational Cancer Institute (NCI)·Phase 1·NCT05685602·43 enrolled

Metastatic Colorectal Adenocarcinoma1 trial

Phase I Clinical Trial of CA-4948 (Emavusertib) in Combination With FOLFOX Plus Bevacizumab as Frontline Treatment in Patients With Metastatic Colorectal Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06696768·24 enrolled

Metastatic Urothelial Carcinoma1 trial

Phase 1 Trial of CA-4948 in Combination With Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06439836·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Emavusertib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Emavusertib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Emavusertib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Emavusertib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q2 2029

Trials by Indication[1]

Myelodysplastic Syndrome2 trials

Chronic Lymphocytic Leukemia1 trial

Biliary Tract Cancer1 trial

Central Nervous System Lymphoma1 trial

Acute Myeloid Leukemia1 trial

Metastatic Pancreatic Ductal Adenocarcinoma1 trial

Metastatic Colorectal Adenocarcinoma1 trial

Metastatic Urothelial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News